Navigation Links
BioMed Realty Trust Declares Second Quarter 2010 Common Stock and Preferred Stock Dividends
Date:6/15/2010

SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its board of directors has declared a second quarter 2010 dividend of $0.15 per share of common stock, representing a 7.1% increase over the company's first quarter 2010 dividend of $0.14 per share.  The dividend is equivalent to an annualized dividend of $0.60 per common share.

BioMed also announced that its board of directors has declared a dividend of $0.46094 per share of the company's 7.375% Series A Cumulative Redeemable Preferred Stock for the period from April 16, 2010 through July 15, 2010.  

Both dividends are payable on July 15, 2010 to stockholders of record at the close of business on June 30, 2010.  

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed owns or has interests in 73 properties, representing 120 buildings with approximately 11.0 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions and developments, and the ability to refinance indebtedness as it comes due; failure to maintain the company's investment grade credit ratings with the ratings agencies; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
2. BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends
3. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
4. Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test
5. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
6. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
7. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
8. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
9. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
10. Environmental Tectonics Corporations BioMedical Division Announces New Contract
11. Avery Biomedical Devices, Inc. Appoints Elefteriades to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017 Cousins Properties (NYSE: CUZ ) ... companies, has signed a 10-year, approximately 125,000 square-foot lease at ... located in the Westshore submarket of Tampa, FL. ... has chosen Corporate Center for their new location in ... and chief executive officer of Cousins Properties. "Amgen is a ...
(Date:3/27/2017)... March 27, 2017  Perthera,s Chief Bioinformatics Officer and ... Subha Madhavan , Ph.D., will be speaking at the ... On Monday, March 27, 2017, she will be speaking ... Usable for Research and Care" (from 10:30 a.m. – ... she will be a participant in the "Making Precision ...
(Date:3/27/2017)... March 27, 2017  Trovagene, Inc. (NASDAQ: TROV), a ... Executive Officer, Bill Welch , will be presenting ... at 9:00 AM EDT at the Essex House in ... and Chief Scientific Officer, Mark Erlander , Ph.D., ... the conference.   The presentation will be webcast ...
(Date:3/24/2017)... ROCKVILLE, Md. , March 24, 2017  Infectex ... Fund (MBVF), today announced positive results of a Phase ... drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis ... by scientists at Sequella, Inc. ( USA ... A total of 140 patients were enrolled ...
Breaking Biology Technology:
(Date:3/2/2017)... -- Who risk to be deprived of its imprint ... https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG CONFRONT ... sensors using capacitive technology represent a fast growing market, ... an increase of 360% of the number of fingerprint ... sensor market between 2014 and 2017 (source : N+1 ...
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
(Date:2/24/2017)...  EyeLock LLC, a leader of iris-based identity ... biometric solution on the latest Qualcomm® Snapdragon™ 835 ... World Congress 2017 (February 27 – March ... 3, Stand 3E10. The Snapdragon ... platform—a combination of hardware, software and biometrics ...
Breaking Biology News(10 mins):